Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|November 24, 2021
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective studyWenxian Wang, Xiaodong Gu, Liping Wang, et al.
Frontiers in Oncology|July 23, 2020
Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab MonotherapyMeilin Jiang, Wenying Peng, Xingxiang Pu, et al.
Frontiers in Immunology|June 24, 2026
First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort studyWan Zhang, Xiaojun Yang, Hualin Chen, et al.
Translational Lung Cancer Research|November 17, 2022
The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort studyBolin Chen, Jingyi Wang, Xingxiang Pu, et al.
Cancer Medicine|December 10, 2022
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective studyXingxiang Pu, QianZhi Wang, Liyu Liu, et al.
Translational Lung Cancer Research|January 9, 2026
Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort studyYu Zhou, Zihan Wei, Min Li, et al.
Chinese Medical Journal|September 23, 2024
The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective studyLingjuan Chen, Yi Kong, Fan Tong, et al.
Analytical Chemistry|January 14, 2026
Plug-and-Play Photo-Initiated CRISPR-Cas12a One-Pot Nucleic Acid Detection via Universal Repeat RNA Acylation StrategyJinlian Du, Xingxiang Pu, Tongyan Yuan, et al.
Advances in Therapy|May 12, 2025
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized TrialsXingxiang Pu, Jiawei Shou, Zemin Xiao, et al.
Oncoimmunology|January 4, 2018
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapyXiang Yan, Li Wang, Ran Zhang, et al.
Pageof 8